Nothing Personal: Disturbing Undercurrents in Cancer Care
Used in medical education.
Includes referenced discussion sections for evidence-based practice.
- Medical Journalists' Association Open Book Award
"A landmark for the patient voice"
- Macmillan Cancer Support
"A remarkable book... essential reading for all who deal with cancer patients - health professionals, politicians, health service developers, carers and, of course, patients themselves... will surely inspire change."
- Professor Karol Sikora in his foreword.
Category Archives: clinical trials
Breast screening, health checks and psychological tactics for GPs to encourage attendance, despite ineffectiveness and harms!
https://www.healthwatch-uk.org/images/Newsletters/Number_104.pdf If you enjoy the series ‘Yes, Minister’ you will probably love Issue 104, 2016-17 of the HealthWatch charity’s Newsletter, especially pages 6-8. Breast screening, health checks, nsaids, …what doesn’t work? In his acceptance speech, HealthWatch Award Winner Peter Gotzsche … Continue reading
An important paper by Kirsten McCaffery and colleagues looks at the problem of overdiagnosis in healthcare and discusses what is needed: ‘Communication that empowers the public, patients, clinicians, and policy makers to think differently about overdiagnosis will help support a … Continue reading
An article in JAMA, 18th January 2016 raises concerns regarding the issue of science being disregarded in response to political pressures: ‘…Regarding its updated guidelines, the Task Force wrote, “the USPSTF cannot reinterpret the science and exaggerate the net benefit … Continue reading
Here is a breast screening leaflet that shows women what they really need to know before deciding whether breast screening is for them. It puts women’s risk into perspective, as well as showing the remote chance of any benefit. Bour … Continue reading
How valid is the use of all-cause mortality in randomized screening trials? In the light of overdiagnosis, overtreatment and resultant deaths, should all-cause mortality be the end point in randomized screening trials? This paper examines the validity of disease-specific deaths … Continue reading